SUNNYVALE, Calif., May 15 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 2008 Citi Investment Research Global Healthcare Conference. Xoft president and CEO, Michael Klein, will present on Wednesday, May 21, 2008, at 11 AM at The Hilton New York.
“We are excited to provide updates on the productive year we have had building momentum for Xoft’s technology platform designed to deliver localized, isotope-free radiation treatment in minimally-shielded clinical settings. We continue to see excellent clinical results with breast cancer, our first FDA cleared indication, and have recently completed enrollment of our voluntary post-market clinical study,” said Klein. “In a significant validation of this important new cancer treatment delivery method, we recently received expanded clearance from the FDA for the Axxent System, making it available for use in the treatment of other cancers or conditions where radiation therapy is indicated. This expanded clearance is very significant as it validates that the FDA recognizes Electronic Brachytherapy is a platform technology that is viable for treatment of conditions outside of the breast.
“In another significant validation of Electronic Brachytherapy, our early commercial sites have experienced good reimbursement with appropriate payment levels. Combined with growing market support, this serves as the foundation for expansion into new treatment areas and fuels continued market adoption of this important technology,” added Klein.
As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications. Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which received FDA clearance on May 12, 2008.
Designed to deliver electronic, X-ray-based radiation treatment, the Axxent treatment platform can be used in virtually any clinical setting under the supervision of a radiation oncologist. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently.
In its treatment of early stage breast cancer, the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.
About Xoft, Inc.
Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft’s first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer and endometrial and rectal indications. Xoft’s solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.
Axxent is a registered trademark of Xoft, Inc.
CONTACT: Chris K. Joseph, +1-510-339-2293, chris@ckjcomm.com, for Xoft,
Inc.
